TB-500 and MK-677 (Ibutamoren): When to Pick One, the Other, or the Full Stack

What TB-500 and MK-677 Actually Do, and Why Women Are Using Them

Each compound works through a distinct pathway. Understanding that distinction is the first step toward deciding whether you need one or both.

TB-500 is a synthetic version of the active region of thymosin beta-4, a naturally occurring 43-amino-acid peptide found at high concentrations in platelets and wound fluid. Its main actions include sequestering G-actin to promote cell motility, reducing pro-inflammatory cytokines, and accelerating tissue remodeling after injury. Research in animal models shows benefit in cardiac, tendon, and corneal repair. Women using TB-500 typically report faster recovery from connective tissue injuries, reduced joint pain, and, anecdotally, improved skin quality.

MK-677 is not technically a peptide. It is an orally active, non-peptide ghrelin receptor agonist that stimulates pituitary growth hormone release. A 12-month RCT in older adults (Nuttall et al., Journal of Clinical Endocrinology and Metabolism, 2008) found that 25 mg daily raised IGF-1 by approximately 60% and lean mass by about 1.5 kg. The trial enrolled men and women, though sex-stratified results were not published separately, which is a meaningful evidence gap for women readers.

Why women specifically are asking about this stack

Women make up a growing share of the functional-medicine and longevity-peptide space. The most common reasons women seek this combination include:

• Persistent tendon or joint injuries that do not resolve with standard physical therapy
• Perimenopause-related muscle loss (sarcopenia begins accelerating after 40 in women)
• Postpartum connective tissue laxity, particularly pelvic floor and abdominal fascia
• PCOS-related body composition concerns, where GH signaling is frequently disrupted
• Aesthetic recovery after surgical procedures

The honest answer is that practitioner-reported outcomes, not controlled trial data, are driving most of these decisions right now.

The Evidence Base: What We Actually Know (and What We Don't)

Both compounds have meaningful preclinical data. Human trial data is thinner, sex-specific data thinner still.

TB-500: animal evidence is strong, human RCT data is nearly absent

Thymosin beta-4 has been studied in animal models of myocardial infarction, corneal injury, and dermal wound healing with consistent positive results. A phase II trial in dry eye disease (RegeneRx, 2012) used topical thymosin beta-4 and showed statistically significant improvement in corneal staining scores. No published RCT has tested injectable synthetic TB-500 in women for musculoskeletal recovery.

The field is largely running on case series and observational data from sports medicine practitioners. Women have been particularly underrepresented even in these smaller reports. Any claimed dose-response relationship for TB-500 in women is extrapolated from male-predominant data or animal studies.

MK-677: more human data, but still limited in women

MK-677 has been tested in several clinical trials. The Nuttall 2008 trial showed sustained IGF-1 elevation without tachyphylaxis over 12 months. A 2008 study in growth hormone-deficient adults showed similar anabolic effects. A key concern raised in the literature is insulin resistance: MK-677 raises fasting glucose modestly in some participants, which is directly relevant to women with PCOS who already carry baseline insulin resistance.

The WomanRx Evidence-Tier Framework for This Stack:

| Tier | Claim | Evidence quality | |------|-------|-----------------| | 1 | TB-500 promotes tissue repair in animals | Consistent across species | | 2 | MK-677 raises IGF-1 ~60% in humans | One 12-month RCT, mixed sex | | 3 | Stack produces additive recovery benefit in women | No RCT; practitioner-reported only | | 4 | Specific female dosing is optimized | No data; all doses extrapolated |

Being clear about these tiers matters. A woman making a decision about these compounds deserves to know she is working from Tier 3 and 4 evidence for the stack itself.

Sex-Specific Physiology: How Being a Woman Changes the Picture

Growth hormone, IGF-1, and the female cycle

Women have naturally higher GH pulse frequency than men, though lower pulse amplitude. Estrogen is a primary driver: it amplifies GH secretion at the pituitary level. This means women's GH axis responds differently to secretagogues than men's, and doses calibrated in male subjects may produce exaggerated IGF-1 responses in women, particularly during the follicular phase when estrogen is rising.

During perimenopause, estrogen decline suppresses GH pulsatility. IGF-1 drops alongside it. Some practitioners argue this creates a rationale for GH-axis support with MK-677 in perimenopausal women, but the interaction between MK-677 and declining estrogen has not been studied in a dedicated trial.

Thymosin beta-4 and hormonal context

Thymosin beta-4 receptors are present in reproductive tissues. Animal data shows thymosin beta-4 expression varies across the estrous cycle. The clinical meaning of this in women using exogenous TB-500 is unknown. No human study has tracked TB-500 pharmacokinetics across the menstrual cycle.

PCOS: a specific caution with MK-677

Women with PCOS already have elevated LH pulsatility and frequently elevated IGF-1. Adding MK-677, which raises IGF-1 further, could theoretically worsen androgen production (IGF-1 stimulates ovarian androgen synthesis) and deepen insulin resistance. This is not a confirmed harm, but it is a mechanism-based concern that warrants caution and warrants monitoring fasting glucose, insulin, and free androgen index before and during use.

Dosing Protocols: What Practitioners Are Currently Using in Women

No approved dosing schedule exists for either compound in women. The following reflects practitioner-reported approaches in the functional-medicine and sports medicine communities.

TB-500 dosing for women

Loading phase: 5 mg twice weekly for 4-6 weeks, administered by subcutaneous or intramuscular injection.

Maintenance phase: 2-5 mg once weekly, or every 10-14 days, for as long as the tissue issue is active.

Some practitioners use a lower loading dose of 2.5 mg twice weekly in women, on the rationale that women have lower average body mass and potentially different receptor sensitivity. This is empirical, not evidence-based.

MK-677 dosing for women

Starting dose: 12.5 mg nightly, oral. This is half the 25 mg dose most commonly studied in trials.

Titration: some practitioners increase to 25 mg after 4-6 weeks if IGF-1 response is subtherapeutic (target IGF-1 mid-to-upper normal for age).

Timing: nightly dosing aligns with physiologic GH peaks during sleep. MK-677 amplifies these peaks rather than creating a flat pharmacologic elevation.

Stack protocol timing

When combining both:

1. Baseline labs first: IGF-1, fasting glucose, insulin, HbA1c, free testosterone (especially in PCOS), estradiol, and LH.
2. Start MK-677 at 12.5 mg nightly for 2-4 weeks before adding TB-500. This lets you attribute any early side effects (water retention, increased appetite, mild glucose rise) to MK-677 alone.
3. Add TB-500 at the loading dose once MK-677 is tolerated.
4. Recheck IGF-1 and fasting glucose at 6-8 weeks.
5. Do not exceed 6 months of continuous use without a planned break and lab reassessment.

When to Pick One Over the Stack

This is the question most women actually want answered, and it deserves a direct answer rather than a generic "it depends."

Use TB-500 alone if:

• Your primary goal is acute or chronic connective tissue repair (tendinopathy, post-surgical fascia, pelvic floor laxity).
• You have PCOS, insulin resistance, or elevated IGF-1 at baseline. Adding MK-677 on top of an already-elevated IGF-1 carries more risk than benefit.
• You are postpartum and thinking about tissue recovery. See the pregnancy section below before proceeding at all.
• You are in the reproductive years and actively monitoring cycle regularity. MK-677's effect on GH/IGF-1 has theoretical implications for LH/FSH feedback that have not been studied.

Use MK-677 alone if:

• Your primary concern is age-related muscle loss (sarcopenia) or poor sleep quality, with no significant active injury.
• You are perimenopausal or postmenopausal with documented low IGF-1 and want GH-axis support.
• You want an oral option. TB-500 requires injection; MK-677 does not.
• Your budget is a factor. MK-677 is generally less expensive per month of use than TB-500.

Use both if:

• You have a significant musculoskeletal injury AND are experiencing age-related muscle or recovery decline simultaneously.
• You are working with a practitioner who can monitor IGF-1, glucose, and body composition labs throughout.
• You are postmenopausal with low IGF-1 confirmed on bloodwork and have a connective tissue issue that is not responding to standard care.
• You have set a defined duration (8-12 weeks loading, then reassessment) rather than running the stack indefinitely.

Pregnancy, Lactation, and Contraception: Read This Before Starting

Both TB-500 and MK-677 are contraindicated in pregnancy. Discontinue both at least one full menstrual cycle, and ideally 2-3 months, before any planned conception attempt.

TB-500 in pregnancy

No human data exists on TB-500 use in pregnancy. Thymosin beta-4 is a naturally occurring peptide with roles in embryogenesis. Exogenous administration of an active fragment during organogenesis carries theoretical teratogenic risk that cannot be dismissed. Animal studies show thymosin beta-4 is expressed in the developing embryo and is involved in cardiac and vascular development. Disrupting this system exogenously is not a risk worth taking. TB-500 has no FDA pregnancy category because it is not FDA-approved for any indication.

If you become pregnant while using TB-500, stop immediately and notify your obstetric provider.

MK-677 in pregnancy

MK-677 raises GH and IGF-1. Elevated IGF-1 in pregnancy has been associated with altered fetal growth trajectories. No human safety data exists for MK-677 in pregnant women. GH-axis manipulation during pregnancy is not considered safe by any current guideline. The FDA has not approved MK-677 for any indication; it remains an investigational compound.

Lactation

Neither compound has lactation transfer data in humans. On the precautionary principle, neither should be used while breastfeeding. IGF-1 is present in breast milk physiologically; whether exogenously elevated maternal IGF-1 from MK-677 translates to elevated infant exposure is unknown.

Contraception requirement

If you are using either compound and are not trying to conceive, use reliable contraception throughout the course and for at least one full cycle after stopping. Discuss your contraception method with your prescribing provider. Combined oral contraceptives raise SHBG and alter the estrogen milieu that influences GH pulsatility, which is relevant if you are using MK-677 for GH-axis support while on the pill.

Who This Stack Is Right For, and Who Should Avoid It

Reproductive years (roughly 18-40)

Proceed with significant caution. This is the life stage with the highest likelihood of unplanned pregnancy, the most PCOS diagnoses, and the least tolerance for IGF-1 elevation. TB-500 alone for acute injury is a more defensible choice than the full stack. Any woman in this age group using MK-677 should be monitoring glucose and IGF-1 every 6-8 weeks and using reliable contraception.

Trying to conceive or undergoing fertility treatment

Do not use either compound. The mechanisms are too intertwined with LH, GH, and IGF-1 signaling, all of which are critical to folliculogenesis and implantation. ASRM guidelines on fertility treatments do not include peptide secretagogues in any assisted reproduction protocol.

Perimenopause (typically 40-52)

This may be the life stage where MK-677 has the strongest rationale, given estrogen-driven GH decline and accelerating muscle loss. A 2019 analysis in the Journal of Clinical Endocrinology noted that GH secretion declines roughly 14% per decade in adults. Adding TB-500 for joint support alongside MK-677 for body composition is a coherent strategy, provided glucose is monitored. Women in perimenopause often have worsening insulin sensitivity, and MK-677's glucose effects are dose-dependent.

Postmenopause

Confirmed low IGF-1, established sarcopenia, and freedom from pregnancy concern make this the group with the most favorable risk-benefit calculation for MK-677. TB-500 for joint and connective tissue support is additive. Regular mammography and breast health surveillance matter here: IGF-1 is a known growth factor for breast tissue, and elevating it in women with a personal or family history of hormone-sensitive breast cancer requires a direct conversation with an oncologist before starting.

Women with PCOS

TB-500 alone may be appropriate for injury recovery. MK-677 should be used with caution, if at all, given the IGF-1 and insulin resistance concerns outlined above. If a prescribing provider recommends MK-677 in a woman with PCOS, baseline and follow-up labs should include fasting insulin, HOMA-IR, free testosterone, and IGF-1.

Side Effects Women Report Most Often

TB-500:

• Mild fatigue in the first week of loading (most common)
• Transient headache
• Injection-site redness or irritation
• Rare: reported flare of pre-existing inflammatory conditions (mechanism unclear)

MK-677:

• Increased appetite, often significant and bothersome in women trying to manage weight
• Water retention and bloating, particularly in the first 2-4 weeks
• Morning lethargy if taken too late at night
• Mild fasting glucose elevation (clinically relevant in women with PCOS or pre-diabetes)
• Vivid dreams (attributed to altered GH sleep architecture)
• Mild tingling in hands (carpal tunnel-like, typically resolves with dose reduction)

A 2008 trial reported that increased appetite was the most common adverse effect of MK-677 at 25 mg, occurring in roughly 20% of participants. Women generally report this effect as more new to their daily lives than men in the same practitioner reports, possibly due to differences in appetite-regulating hormones including leptin and ghrelin.

Labs to Check Before, During, and After

This is not optional if you are using either compound. Responsible use requires a monitoring plan.

Before starting:

• IGF-1 (to establish baseline and confirm whether MK-677 is even indicated)
• Fasting glucose and insulin, HbA1c
• Estradiol, LH, FSH (to understand hormonal context)
• Free testosterone and DHEA-S (especially in PCOS)
• Liver enzymes and basic metabolic panel
• Pregnancy test

At 6-8 weeks:

• IGF-1 (target: mid-to-upper normal range for your age, not supraphysiologic)
• Fasting glucose
• Body composition if available (DEXA or InBody)

At completion of loading phase (10-12 weeks):

• Full repeat panel
• Clinical reassessment of the original indication

If IGF-1 exceeds the upper limit of the normal range for your age, reduce MK-677 dose before continuing.